The tumor-inhibiting functions of CCT3 silencing in melanoma were associated with CDK1 downregulation in the cell cycle signaling pathway, which might provide novel markers and targets for melanoma diagnosis and treatment. This evidence concerns the gene CDK1 and neoplasm.